$-0.39 EPS Expected for Momenta Pharmaceuticals, Inc. (MNTA)

October 14, 2018 - By Marguerite Chambers

Investors sentiment increased to 1.33 in Q2 2018. Its up 0.23, from 1.1 in 2018Q1. It improved, as 17 investors sold Momenta Pharmaceuticals, Inc. shares while 40 reduced holdings. 25 funds opened positions while 51 raised stakes. 74.20 million shares or 3.06% more from 72.00 million shares in 2018Q1 were reported.
Aqr Management Ltd Llc reported 30,287 shares stake. Ftb Advsrs holds 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) or 656 shares. Arizona State Retirement System invested in 112,906 shares. Huntington Savings Bank owns 125 shares. Quantbot Lp owns 2,231 shares. Hbk Invests Limited Partnership reported 18,700 shares. Voya Management Limited Liability has invested 0% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). Franklin Res owns 878,100 shares. Balyasny Asset Mgmt Limited has invested 0.03% in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA). United Services Automobile Association reported 0.09% stake. Credit Suisse Ag owns 67,938 shares for 0% of their portfolio. Aperio Limited invested in 21,371 shares or 0% of the stock. 34,354 were reported by Guggenheim Capital Limited Liability. 18,065 were accumulated by Piedmont Investment Llc. Pinebridge Invs Limited Partnership reported 0.01% stake.

Since April 12, 2018, it had 0 insider buys, and 28 selling transactions for $4.99 million activity. Stoner Elizabeth sold 4,152 shares worth $113,474. 581 shares were sold by Kaundinya Ganesh Venkataraman, worth $15,832. Leicher Bruce had sold 351 shares worth $8,213 on Monday, May 21. The insider WHEELER CRAIG A sold $45,937. Arroyo Santiago also sold $59,163 worth of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) shares. 2,294 shares were sold by GILMAN STEVEN C, worth $49,321 on Friday, June 22.

Analysts expect Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) to report $-0.39 EPS on November, 7.They anticipate $0.05 EPS change or 11.36 % from last quarter’s $-0.44 EPS. After having $-0.91 EPS previously, Momenta Pharmaceuticals, Inc.’s analysts see -57.14 % EPS growth. The stock decreased 13.49% or $2.51 during the last trading session, reaching $16.1. About 1.90M shares traded or 252.26% up from the average. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) has risen 60.45% since October 14, 2017 and is uptrending. It has outperformed by 44.83% the S&P500.

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company has market cap of $1.26 billion. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE. It currently has negative earnings. The Company’s biosimilars programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M834, a biosimilar of ORENCIA for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, as well as other biosimilar candidates.

More notable recent Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) news were published by: Seekingalpha.com which released: “European advisory group back’s Melinta’s dual antibiotic Vabomere” on September 21, 2018, also Nasdaq.com with their article: “Recent Analysis Shows RadNet, Electro Scientific Industries, Koppers, Momenta Pharmaceuticals, IQVIA, and …” published on October 11, 2018, Benzinga.com published: “44 Biggest Movers From Yesterday” on October 12, 2018. More interesting news about Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) were released by: Seekingalpha.com and their article: “Momenta Pharmaceuticals completes strategic review to refocus its operations and drive shareholder value” published on October 01, 2018 as well as Benzinga.com‘s news article titled: “41 Stocks Moving In Friday’s Mid-Day Session” with publication date: October 12, 2018.

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News